{"id":1191,"date":"2022-08-12T14:40:02","date_gmt":"2022-08-12T18:40:02","guid":{"rendered":"https:\/\/www.allergy-associates.com\/?p=1191"},"modified":"2022-08-12T14:40:02","modified_gmt":"2022-08-12T18:40:02","slug":"new-treatment-for-hae-hane","status":"publish","type":"post","link":"https:\/\/www.allergy-associates.com\/?p=1191","title":{"rendered":"New Treatment for HAE (HANE)"},"content":{"rendered":"\n<p><em>The New England Journal of Medicine<\/em> recently published research done at the University of California on a new treatment for hereditary angioneurotic edema (HANE) also called hereditary angioedema (HAE).&nbsp;<\/p>\n\n\n\n<p>HANE or HAE is a rare genetic disorder that leads to unpredictable, disabling and occasionally fatal episodes of swelling.&nbsp; The swelling can occur in any part(s) of the body.&nbsp; It is caused by uncontrolled activity of the contact system components factor X11a and plasma Kallikrein which leads to excessive release of a bradykinin which in turn causes leaky blood vessels (vascular permeability) with the resultant swelling from the fluid that leaks out of the blood vessels.&nbsp;<\/p>\n\n\n\n<p>The most common form is due to reduced production or reduced functionality of a controller protein called C-1-esterase inhibitor.&nbsp; But there are other forms including ones with normal C-1-inhibitor.<\/p>\n\n\n\n<p>This latter group has been difficult to treat with most current therapies because they work by increasing production of function of C-1-inhibitor replace it directly or inhibit Kallikrein or block the bradykinin receptor.&nbsp; The currently available therapies can be used either to treat\/stop acute attacks or prophylactically.&nbsp; In general, they work quite well but not 100%.&nbsp; That is why improved therapies are being researched.&nbsp;<\/p>\n\n\n\n<p>The new drug being researched is donidalorsen which is an antisense oligonucleotide that selectively inhibits plasma prekallikrein production.&nbsp; (Say what?)&nbsp;&nbsp; Donidalorsen inhibits the production of plasma prekallikrein by means of ribonuclease (RNase) enzyme that degrades messenger RNA that would otherwise lead to prekallikrein production.&nbsp; The idea is by moving a step earlier in the domino-like chain of events by reducing prekallikrein this will prevent kallikrein and eventually bradykinin.&nbsp;<\/p>\n\n\n\n<p>The UC researchers have conducted a small trial in 32 patients with a 90% reduction in attacks.&nbsp; Moreover, the medication was not prone to causing side effects.&nbsp; Larger trials are underway.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The New England Journal of Medicine recently published research done at the University of California on a new treatment for hereditary angioneurotic edema (HANE) also called hereditary angioedema (HAE).&nbsp; HANE or HAE is a rare genetic disorder that leads to unpredictable, disabling and occasionally fatal episodes of swelling.&nbsp; The swelling can occur in any part(s) of the body.&nbsp; It is caused by uncontrolled activity of the contact system components factor X11a and plasma Kallikrein which leads to excessive release of&#8230;<\/p>\n<p class=\"read-more\"><a class=\"btn btn-default\" href=\"https:\/\/www.allergy-associates.com\/?p=1191\"> Read More<span class=\"screen-reader-text\">  Read More<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[578,258,577],"class_list":["post-1191","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-angioneurotic-edema","tag-hae","tag-hane"],"_links":{"self":[{"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=\/wp\/v2\/posts\/1191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1191"}],"version-history":[{"count":1,"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=\/wp\/v2\/posts\/1191\/revisions"}],"predecessor-version":[{"id":1192,"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=\/wp\/v2\/posts\/1191\/revisions\/1192"}],"wp:attachment":[{"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.allergy-associates.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}